Asymptomatic and Symptomatic SARS-CoV-2 Infections After BNT162b2 Vaccination in a Routinely Screened Workforce

https://jamanetwork.com/journals/jama/fullarticle/2779854

Li Tang, Diego R. Hijano, Aditya H. Gaur, Terrence L. Geiger, Ellis J. Neufeld, James M. Hoffman, Randall T. Hayden

Evaluación: (not yet rated)

Resumen	A 2-dose regimen of the BNT162b2 vaccine (Pfizer-BioNTech) against SARS-CoV-2 was authorized in December 2020 based on reported 94.8% efficacy. Although an association between vaccination and a reduction in symptomatic disease has been well described, an association with asymptomatic infection remains unclear.
Procedencia del autor	Extranjero

Resumen

A 2-dose regimen of the BNT162b2 vaccine (Pfizer-BioNTech) against SARS-CoV-2 was authorized in December 2020 based on reported 94.8% efficacy. Although an association between vaccination and a reduction in symptomatic disease has been well described, an association with asymptomatic infection remains unclear.

Procedencia del autor

Extranjero

Texto completo	jama_tang_2021_ld_210029_1624316986.31235.pdf

Tipo de documento	Vacunas
Especialidad(es)	Especialidades básicas biomédicas -- Inmunología

Publicado en el sitio	2021-07-14 09:34:25

Reportar cualquier problema con este Recurso

Comentarios

(aún no hay comentarios disponibles para este recurso)

Al DÍA - Enfermedades Infecciosas

Publicaciones covid-9

Asymptomatic and Symptomatic SARS-CoV-2 Infections After BNT162b2 Vaccination in a Routinely Screened Workforce

Comentarios